Fujian Cosunter Pharmaceutical Co Ltd Net Asset Quality Index
Fujian Cosunter Pharmaceutical Co Ltd net asset quality index. Fujian Cosunter Pharmaceutical Co Ltd (300436) has a Net Asset Quality Index of 20.4% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.34 Billion minus total liabilities of CN¥1.07 Billion yields net assets of CN¥272.54 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check earnings quality score of Fujian Cosunter Pharmaceutical Co Ltd to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Fujian Cosunter Pharmaceutical Co Ltd (2011–2025)
Net asset quality index of Fujian Cosunter Pharmaceutical Co Ltd from 2011 to 2025. This chart shows how Fujian Cosunter Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the index stands at 20.4%, representing net assets of CN¥272.54 Million against total assets of CN¥1.34 Billion CNY. See 300436 book value for net asset value and shareholders' equity analysis.
Fujian Cosunter Pharmaceutical Co Ltd Net Asset Quality Index by Year (2011–2025)
Fujian Cosunter Pharmaceutical Co Ltd net asset quality index by year from 2011 to 2025. The table below presents the year-by-year Net Asset Quality Index for Fujian Cosunter Pharmaceutical Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Fujian Cosunter Pharmaceutical Co Ltd stock valuation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 24.7% | CN¥346.30 Million | CN¥1.40 Billion | CN¥1.05 Billion | ▼ -2.8 pp |
| 2024 | 27.6% | CN¥396.78 Million | CN¥1.44 Billion | CN¥1.04 Billion | ▼ -7.7 pp |
| 2023 | 35.3% | CN¥569.24 Million | CN¥1.61 Billion | CN¥1.05 Billion | ▼ -28.7 pp |
| 2022 | 63.9% | CN¥955.62 Million | CN¥1.49 Billion | CN¥539.22 Million | ▼ -8.6 pp |
| 2021 | 72.6% | CN¥1.05 Billion | CN¥1.45 Billion | CN¥396.92 Million | ▲ +14.7 pp |
| 2020 | 57.8% | CN¥581.99 Million | CN¥1.01 Billion | CN¥424.10 Million | ▼ -6.2 pp |
| 2019 | 64.0% | CN¥573.74 Million | CN¥896.25 Million | CN¥322.51 Million | ▼ -1.8 pp |
| 2018 | 65.8% | CN¥562.35 Million | CN¥854.68 Million | CN¥292.33 Million | ▼ -9.2 pp |
| 2017 | 75.0% | CN¥552.05 Million | CN¥736.47 Million | CN¥184.42 Million | ▼ -3.9 pp |
| 2016 | 78.8% | CN¥552.36 Million | CN¥700.67 Million | CN¥148.30 Million | ▼ -7.6 pp |
| 2015 | 86.4% | CN¥519.20 Million | CN¥600.70 Million | CN¥81.50 Million | ▲ +16.4 pp |
| 2014 | 70.0% | CN¥156.87 Million | CN¥224.11 Million | CN¥67.24 Million | ▼ -2.5 pp |
| 2013 | 72.4% | CN¥143.10 Million | CN¥197.53 Million | CN¥54.42 Million | ▼ -0.2 pp |
| 2012 | 72.7% | CN¥108.59 Million | CN¥149.41 Million | CN¥40.82 Million | ▲ +12.8 pp |
| 2011 | 59.9% | CN¥65.43 Million | CN¥109.29 Million | CN¥43.86 Million | — |